|
![]() |
|
|
Hydroxyurea
drug data and news
Hydroxyurea drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Hydroxyurea | ||
| Brand Names/Synonyms | Biosupressin; CCRIS 958; Carbamohydroxamic Acid; Carbamohydroximic Acid; Carbamohydroxyamic Acid; Carbamoyl Oxime; Carbamyl Hydroxamate; DRG-0253; Droxia; HU; Hidrix; Hydrea; Hydreia; Hydroxicarbamidum; Hydroxycarbamide; Hydroxycarbamine; Hydroxylurea; Hydroxyurea; Hydura; Hydurea; Idrossicarbamide [Dcit]; Litaler; Litalir; N-Carbamoylhydroxylamine; N-Hydroxyurea; Onco-Carbide; Oxyurea; SQ 1089; Sterile Urea; Ureaphil | ||
| Indication | For management of melanoma, resistant chronic myelocytic leukemia, and recurrent, metastatic, or inoperable carcinoma of the ovary and Sickle-cell anemia | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Hydroxyurea has dose-dependent synergistic activity with cisplatin in vitro. in vivo Hydroxyurea showed activity in combination with cisplatin against the LX-1 and CALU-6 human lung xenografts, but minimal activity was seen with the NCI-H460 or NCI-H520 xenografts. Hydroxyurea was synergistic with cisplatin in the Lewis lung murine xenograft. Sequential exposure to Hydroxyurea 4 hours before cisplatin produced the greatest interaction. | ||
| Mechanism Of Action | Hydroxyurea is converted to a free radical nitroxide (NO) in vivo, and transported by diffusion into cells where it quenches the tyrosyl free radical at the active site of the M2 protein subunit of ribonucleotide reductase, inactivating the enzyme. The entire replicase complex, including ribonucleotide reductase, is inactivated and DNA synthesis is selectively inhibited, producing cell death in S phase and synchronization of the fraction of cells that survive. Repair of DNA damaged by chemicals or irradiation is also inhibited by hydroxyurea, offering potential synergy between hydroxyurea and radiation or alkylating agents. Hydroxyurea also increases the level of fetal hemoglobin, leading to a reduction in the incidence of vasoocclusive crises in sickle cell anemia. Levels of fetal hemoglobin increase in response to activation of soluble guanylyl cyclase (sGC) by hydroxyurea-derived NO. | ||
| Hydroxyurea News (When available) |
Simple Test Could Predict Major Complications in Sickle Cell ... 07 Mar 2006 Yuet Wai Kan, MD Sickle Cell and Thalassemia Pioneer Feb 28, 2006 Icagen Reports Fourth Quarter and Full Year 2005 Financial Results Mar 1, 2006 Icagen Reports Fourth Quarter and Full Year 2005 Financial Results Mar 1, 2006 GenoMed Trial Results: Sickle Cell Disease - From Daily Pain to ... Feb 22, 2006 The Susceptibility of Granulosa Cells to Apoptosis is Influenced ... Feb 14, 2006 Warning for Blood Drug Hydroxyurea Jan 27, 2006 Stroke risk returns when children with sickle cell disease stop ... Jan 15, 2006 Icagen's Phase III Clinical Trial of ICA-17043 on Course Following ... Jan 30, 2006 Bristol-Myers drugs get new warnings Jan 26, 2006 Sickle cell mutation corrected in mice Jan 9, 2006 Advances in treatment of chronic myeloid leukaemia Jan 13, 2006 New Predictor of Deadly Complication Identified in Sickle Cell ... 12 Dec 2005 New Studies Identify Advances in Treatment Of Chronic Myeloid ... Dec 10, 2005 Gleevec® Plus Hydroxyurea May Have Activity in Glioblastomas Sep 23, 2005 Adult sickle cell drug hydroxyurea proves effective in young ... Sep 20, 2005 BLOOD TEST FOR DIABETES SHOWS BLOOD-SUGAR CONTROL FOR THE PAST FEW ... Sep 30, 2005 Sickle Cell Disease Causes Severe Pain Sep 22, 2005 Adult sickle cell drug good for youngsters Sep 19, 2005 Treatments for Sickle Cell Anemia Sep 13, 2005 Combination of Gleevec® and Hydrea® Offers Promise for ... Sep 21, 2005 Efavirenz may linger for up to eight weeks after treatment stops Sep 27, 2005 $11,000 raised against killer disease Sep 23, 2005 Apple Cider Vinegar: Alternative Medicine Miracle Sep 22, 2005 Can a new combination treatment prevent a secondary stroke in ... Sep 1, 2005 New ways to prevent stroke and reduce excess iron in sickle cell ... Sep 4, 2005 Initiation Of New Study To Help Children With Sickle Cell Anaemia Sep 1, 2005 National Study: New Ways To Prevent Stroke And Reduce Excess Iron ... Sep 1, 2005 New treatment may help with sickle cell Sep 1, 2005 Inherited Disease May Cause Premature Death Sep 1, 2005 Sickle Cell survivors honored Sep 4, 2005 THE FAMILY DOCTOR Aug 23, 2005 Mortality in Sickle Cell Patients on Hydroxyurea Therapy Aug 1, 2005 Older drug better than new for blood cell disorder Jul 6, 2005 CME Questions Aug 1, 2005 New thrombosis drug is less effective and more expensive than the ... Jul 15, 2005 Traditional therapy best for thrombocythemia Jul 13, 2005 Finding to save government millions of pounds Jul 7, 2005 Maxim issued with novel cancer drug patent Jul 25, 2005 Hydrea Trumps Agrylin as First Line Therapy for High Risk ... Jul 6, 2005 | ||
| Dosage Forms | CAPSULE | ||
| Drug_Category | Antisickling Agents; Antineoplastic Agents; ATC:L01A | ||
| Absorption | Well absorbed from the gastrointestinal tract. | ||
| Interactions |
-->Interactions for Hydroxyurea: Prospective studies on the potential for hydroxyurea to interact with other drugs have not been performed. Concurrent use of hydroxyurea and other myelosuppressive agents or radiation therapy may increase the likelihood of bone marrow depression or other adverse events. Since hydroxyurea may raise the serum uric acid level, dosage adjustment of uricosuric medication may be necessary. | ||
| Toxicity | Oral, mouse: LD50 = 7330 mg/kg; Oral, rat: LD50 = 5760 mg/kg Teratogenicity: Teratogenic effects have occurred in experimental animals.Hydroxyurea use during a small number of human pregnancies has been reported. Adverse effects have not been observed in any of the exposed newborns. Reproductive Effects: Adverse reproductive effects have occurred in experimental animals. Mutagenicity: Mutagenic effects have occurred in experimental animals.Mutagenic effects have occurred in humans. | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | hydroxyaminomethanamide | ||
| Chemical Formula | CH4N2O2 | ||
| Molecular Weight | 76.0547 g/mol | ||
| Smiles String | C(=O)(N)NO | ||
| Melting Point | 142-146 °C | ||
| Water Solubility | 1E+006 mg/L | ||
| State | Solid | ||
| LogP/Hphobicity | -1.432 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Hepatic. | ||
| Half Life | 3-4 hours | ||
| Protein Binding [%] | Not Available | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Hydroxyurea.html http://www.rxlist.com/cgi/generic2/hydroxyurea.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00023 | ||
| CAS Registry Number | 127-07-1 | ||
| KEGG Compound ID | C07044 | ||
| PubChem ID | SID:90752 | ||
| PharmGKB ID | PA449942 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 2247937 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |